Revolution Medicines’ daraxonrasib posted detailed, phase 3 results at ASCO that investigators described as practice-changing in metastatic RAS G12-mutant pancreatic cancer. In the trial population with RAS G12 mutations, daraxonrasib nearly doubled survival versus chemotherapy, with a median overall survival reported as 13.2 months for all recipients and 6.6 months for the chemo comparator. Presented at the American Society of Clinical Oncology meeting and published simultaneously in The New England Journal of Medicine, the data also showed longer disease control, including progression-free outcomes that investigators said were consistent across key subgroups. The company’s program targets KRAS G12-driven tumors; the study also evaluated effects across the broader “all-comer” population as a secondary objective. The readout follows earlier topline reporting from Revolution and helped re-ignite investor and clinical focus on targeted second-line approaches in pancreatic cancer, where new options have historically been scarce.